For a long time, researchers were unsure if atopic dermatitis was primarily a barrier disease or an immune-driven disease, but dupilumab has provided a more clear-cut answer, said Emma Guttman-Yassky, MD, PhD, of the Icahn School of Medicine at Mount Sinai Medical Center in New York.
For a long time, researchers were unsure if atopic dermatitis was primarily a barrier disease or an immune-drive disease, but dupilumab has provided a more clear-cut answer, said Emma Guttman-Yassky, MD, PhD, of the Icahn School of Medicine at Mount Sinai Medical Center in New York.
Transcript
How does the immune pathway play a role in atopic dermatitis?
Atopic dermatitis is an evolving field and for many years there was a debate whether it is primarily a barrier disease or primarily an immune-driven disease. There was not a clear-cut answer because the only way to prove it is actually to target specifics to the immune system and to show that you reversed the barrier. And that was not possible really until dupilumab.
There were some hints toward it. There were some immune-based treatments cyclosporine and methotrexate and itolizumab. And they all work, However, they do have some effects on keratinocyte and also they are very broad, so it is not really proving the immune hypothesis. To prove the immune hypthesis you need to take a single cytokine or 2 cytokines, like in this case, target them and then show that you reversed the barrier, and that's proving the immune hypothesis.
And that's exactly what happened here. Because with dupilumab we showed that not only the clinical disease activity was reversed, but by suppressing the cytokines, you also reversed major features of the barrier, such as the thickness, the epidermal hyperplasia. The S100 proteins are increased. You show the trend to improve filaggrin and loricrin.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More